The combined strategies, vaccination of pregnant women against RSV and recommendation of niservimab for infants, were recommended by most members. It is recommended to list a group of clinical conditions for infants to receive niservimab. For example: premature infants (extending the gestational age that has been used in the palivizumab recommendations), other infant health conditions similar to the use of palivizumab (congenital heart disease), Down syndrome and others to be further defined with specialists.

CTAI-HPV subgroup HPV VACCINATION MEETING IN PREPARED PERSONS: PROTOCOL AND IMPLEMENTATION Taking into account the morbidity profile of PrEP users (with increased vulnerability to sexually transmitted infections), as well as the efficacy of the vaccine in reducing lesions related to HPV genotypes, it was unanimously recommended to extend HPV vaccination to PrEP users aged 15-45 years, according to the guidelines below:

Inclusion of the Pre-Exposure rabies vaccine in the NIP vaccination schedule for hard-to-reach areas of the Legal Amazon.